Hemogenyx Pharmaceuticals Plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| HEMO.L | HEM.V | ATORX.ST | PYXS | ONCY | COAG | |
|---|---|---|---|---|---|---|
| Market cap | 38.83M | 11.63M | 38.18M | 198.30M | 55.70M | 2.11B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -0.4 | -0.1 | -1.5 | -2.1 | -17.7 |
| Price/book | 8.9 | -2.0 | 0.3 | 9.2 | -8.7 | 4.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −38.01% | −38.89% | −99.44% | −58.91% | −58.42% | +26.76% |
| Today | −6.94% | +10.00% | 0.00% | +1.22% | +8.92% | +4.62% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All HEMO.L news ›Total current liabilities of HEMOGENYX PHARMACEUTICALS PLC. – OTC:HOPHF
HemoGenyx Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of a suite of products to address current problems associated with the treatment of blood disorders such as…
Hemogenyx Pharmaceuticals PLC Announces Feasibility Study Agreement
Each party retains its technology ownership, while the HG-CT-1 Phase I trial remains unaffected by the laboratory study. LONDON, UK / ACCESS Newswire / October 19, 2026 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical-stage…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.